Elicio Therapeutics(ELTX) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Oppenheimer Maintains Elicio Therapeutics(ELTX.US) With Hold Rating
Moomoo News14:31 ET · Ratings
Express News | Elicio Therapeutics Shares Are Trading Lower After the Company Reported FY24 Financial Results and Missed Its EPS Estimate
Benzinga14:08 ET
Analysts Offer Insights on Healthcare Companies: Bio-Path Holdings (OtherBPTH), SI-Bone (SIBN) and Elicio Therapeutics (ELTX)
TipRanksMar 31 10:10 ET · Ratings
Elicio Therapeutics FY 2024 GAAP EPS $(4.25) Misses $(3.56) Estimate, As Of December 31, 2024, Cash And Cash Equivalents Were $17.6M. Including $10M In Gross Proceeds From January 2025 Registered Direct Offering, The Company Expects Cash Runway Into...
BenzingaMar 31 07:17 ET
Elicio Therapeutics | 10-K: Annual report
SECMar 31 07:08 ET · Announcements
Elicio Therapeutics 2024 Loss/Shr $4.25 >ELTX
Dow JonesMar 31 07:02 ET

Comments

Izz Khairudin

Mar 22 00:41

Worth to keep on eye? Target maybe at least 10.00? Let’s wait and see.

$Elicio Therapeutics (ELTX.US)$ $Elicio Therapeutics (ELTX.US)$

Jaguar8

Jan 22 20:31

NEWS

$Elicio Therapeutics (ELTX.US)$
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
Wednesday, 22nd January at 7:30 am
Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population and primary endpoint analysis
Phase 2 randomized study of ELI-002 fully enrolled, with formal interim analysis of disease-free survival ("DFS") expected in H1 2025; positive results could support rapid advan...

1

Trytosaveabit

Dec 12, 2024 20:13

Update

$Elicio Therapeutics (ELTX.US)$ Elicio Therapeutics Presents Updated Results From ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
GlobeNewswire· 12 mins ago
Updated Phase 1 data include a 16.3-month median recurrence-free survival ("mRFS") and 28.9-month median overall survival ("mOS") from full study population
Strong correlation observed between mRFS and strength of T cell response
Event-driven interim analysis from randomized Phase 2 trial expected in H1 2025

Jaguar8

Dec 12, 2024 20:04

NEWS

$Elicio Therapeutics (ELTX.US)$
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
Thursday, 12th December at 7:00 am
Updated Phase 1 data include a 16.3-month median recurrence-free survival ("mRFS") and 28.9-month median overall survival ("mOS") from full study population
Strong correlation observed between mRFS and strength of T cell response
Event-driven interim analysis from randomized Phase 2 trial expected in H1 20...

Jaguar8

Dec 3, 2024 20:05

NEWS

$Elicio Therapeutics (ELTX.US)$
Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment
Tuesday, 3rd December at 7:00 am
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ: ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the completion of enrollment in the Phase 2 AMPLIFY-7P study (NCT05726864). The randomized Phase 2 st...

ELTX Elicio Therapeutics

Trade Overview

Capital Trend

News

Comments

Market Insights